Drugs / Candidate UTI vaccine HTD formulation 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06702449 | Nov 2024 → May 2027 expected | urinary tract infection | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Candidate UTI vaccine HTD formulation 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06702449 ↗ |
| Modality | Vaccine | “candidate UTI vaccine” NCT06702449 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06702449 ↗ |